Market Place
Sourcing Support
All News #Library
APIs
Micronization Enhances Bioavailability in Dry Powder Inhalers
17 Mar 2026 //
PRESS RELEASE
APIs for Asthma and COPD: Challenges in Inhalation Formulations
05 Mar 2026 //
PRESS RELEASE
Regulatory Pathways for Inhalable APIs in the EU and US
23 Feb 2026 //
PRESS RELEASE
Upcoming Trends in Inhalation Drug Delivery Technologies
12 Feb 2026 //
PRESS RELEASE
How to Select a Strategic API Partner High-Quality Manufacturer
14 Jan 2026 //
PRESS RELEASE
Achieving Batch to-Batch Performance Inhalation API Manufacture
23 Dec 2025 //
PRESS RELEASE
Inke Acquires Pharmanoid For Ophthalmic High Potent API Assets
17 Dec 2025 //
PRESS RELEASE
Inke Applying Quality By Design For Respiratory And Complex APIs
04 Dec 2025 //
PRESS RELEASE
From Particle Size to Performance Understanding API Micronization
04 Nov 2025 //
PRESS RELEASE
What Are Inhalation APIs and Why They Matter in Respiratory Drug
01 Nov 2025 //
PRESS RELEASE
Formoterol Fumarate: Inke’s Flagship API for Respiratory Health
13 May 2025 //
PRESS RELEASE
Inke Expands Its Reach in China with New DMF Approvals
07 Jan 2025 //
PRESS RELEASE
Inke Achieves Aprepitant CEP and Salmeterol DMF A Step Forward
04 Dec 2024 //
PRESS RELEASE
Inke unveils its New Brand Identity reflecting Growth and Innovation
05 Sep 2024 //
PRESS RELEASE
Clifford Chance advises on the financing for Keensight Capital’s acquisition of Inke
21 Jun 2023 //
IBERIANLAWYER
Neuraxpharm Agrees on Divestment of Inhalation API Specialist
23 Apr 2023 //
PR NEWSWIRE
Leading inhalation APIs expert Inke to triple production capacity
20 Apr 2022 //
PRNEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.